Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases
- PMID: 31812657
- DOI: 10.1016/j.cgh.2019.11.052
Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases
Abstract
A treat-to-target strategy with close monitoring of intestinal inflammation is recommended in inflammatory bowel disease (IBD). Ileocolonoscopy remains the gold standard for assessing disease activity in IBD but is a relatively invasive procedure and is impossible to repeat in the context of tight monitoring strategies. In addition to biomarkers, cross-sectional imaging increasingly is used in these patients. Computed tomography is limited by the use of radiation, while the use of magnetic resonance enterography (MRE) is limited by its cost and access. There is growing interest in bowel ultrasound that represents a cost-effective, noninvasive, and well-tolerated modality in clinical practice, but it is operator dependent. Compared with ileocolonoscopy and MRE, bowel US has been shown to have the same level of accuracy in assessing and monitoring disease activity for both CD and UC and thus can be considered a point-of-care test. Diffusion-weighted imaging (DWI) is a MR imaging technique that increasingly is used in both IBD and non-IBD conditions and has been shown to be a valuable and accurate tool for assessing and monitoring IBD activity. Compared with conventional MRE, DWI is quicker, less time consuming, may not require intravenous contrast agent, fasting, bowel cleansing, oral preparation, or rectal preparation. This review discusses the role of these cross-sectional imaging techniques for the management of patients with IBD. In the near future, the value of DWI and ultrasound in assessing IBD will require further investigation in the era of transmural healing in CD and complete mucosal healing, including histologic remission, in ulcerative colitis.
Keywords: Bowel Ultrasound; Crohn’s Disease; Diffusion-Weighted Imaging; Imaging; Inflammatory Bowel Disease; Ulcerative Colitis.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Point-of-Care Ultrasound in Inflammatory Bowel Disease.J Crohns Colitis. 2021 Jan 13;15(1):143-151. doi: 10.1093/ecco-jcc/jjaa151. J Crohns Colitis. 2021. PMID: 32674146 Review.
-
Usefulness of magnetic resonance enterography in detecting signs of sacroiliitis in young patients with inflammatory bowel disease.Pediatr Rheumatol Online J. 2020 Jun 3;18(1):42. doi: 10.1186/s12969-020-00433-w. Pediatr Rheumatol Online J. 2020. PMID: 32493352 Free PMC article.
-
Paediatric magnetic resonance enterography in inflammatory bowel disease.Eur J Radiol. 2018 May;102:129-137. doi: 10.1016/j.ejrad.2018.02.029. Epub 2018 Mar 7. Eur J Radiol. 2018. PMID: 29685526 Review.
-
Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows.J Clin Med. 2022 Jan 12;11(2):353. doi: 10.3390/jcm11020353. J Clin Med. 2022. PMID: 35054047 Free PMC article. Review.
-
Plain magnetic resonance imaging as an alternative in evaluating inflammation and bowel damage in inflammatory bowel disease--a prospective comparison with conventional magnetic resonance follow-through.Scand J Gastroenterol. 2015 May;50(5):519-27. doi: 10.3109/00365521.2014.1003398. Epub 2015 Jan 16. Scand J Gastroenterol. 2015. PMID: 25592192
Cited by
-
Imaging of Ulcerative Colitis: The Role of Diffusion-Weighted Magnetic Resonance Imaging.J Clin Med. 2024 Sep 2;13(17):5204. doi: 10.3390/jcm13175204. J Clin Med. 2024. PMID: 39274415 Free PMC article. Review.
-
Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases.Inflamm Bowel Dis. 2020 Sep 18;26(10):1451-1462. doi: 10.1093/ibd/izaa210. Inflamm Bowel Dis. 2020. PMID: 32812036 Free PMC article.
-
SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience.Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):507-516. doi: 10.1038/s41575-020-0319-3. Epub 2020 Jun 11. Nat Rev Gastroenterol Hepatol. 2020. PMID: 32528139 Free PMC article. Review.
-
Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease.Therap Adv Gastroenterol. 2020 Dec 24;13:1756284820979765. doi: 10.1177/1756284820979765. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 33488771 Free PMC article.
-
An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study.Biomedicines. 2025 Jan 14;13(1):190. doi: 10.3390/biomedicines13010190. Biomedicines. 2025. PMID: 39857773 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical